Screening for brain metastasis in patients with stage III Non-Small Cell Lung Cancer: Has Magnetic Resonance Imaging an additive value compared to contrast enhanced Computed Tomography of the brain Incorporated in the staging whole body 18FDG-PET-CT scanning?

Completed

• Conditions: on Small Cell Lung Cancer, brain metastases, MRI, 18FDG-PET-CT with contrast enhanced CT brainniet kleincellig longkanker, hersenmetastasen, MRI, 18FDG-PET-CT met diagnostische CT van het brein

• Registration Number: NL-OMON25283
• Lead Sponsor: MUMC+

Brief Summary

Schoenmaekers, J., Hendriks, L. E., Hofman, P. et al, JTO 2016; 12:S1:MA06.05 <br><br> Schoenmaekers et al, 1365PD - Screening for brain metastases (BM) in patients (pts) with stage III non-small cell lung cancer (NSCLC), magnetic resonance imaging (MRI) or dedicated contrast-enhanced computed tomography (dCE-CT)? A prospective observational study

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 118

Inclusion Criteria

1. Pathology proven NSCLC;

2. UICC stage III;

Exclusion Criteria

1. Other malignancy that is not controlled or that was diagnosed less than 2 years before enrolment in this study, except skin cancer or cervical cancer in situ;

2. Contra-indication for MRI or CE-CT;

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of patients with additional brain metastasis found on MRI after negative CE-CT.

Secondary Outcome Measures

Name	Time	Method
1. Asymptomatic brain metastasis found on 18FDG-PET-CE-CT in otherwise stage III NSCLC patients;<br /><br>2. Cost analysis;<br /><br>3. Number of patients with symptomatic brain metastasis within a year after an initially negative MRI and time to symptomatic brain metastasis.